Merrimack Pharma (MACK) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Mizuho Securities Reiterates Bullish Stance on Merrimack Pharmaceuticals (MACK) Into MM-398 PDUFA Date
August 11, 2015 7:46 AM EDTMizuho Securities analyst Peter Lawson reiterated an Outperform rating and $16 price target on Merrimack Pharmaceuticals (NASDAQ: MACK) heading into an October 24 PDUFA date for MM-398.
"The company remains one of our favorite biotech plays and we feel it is overlooked by investors, given... More
